There are 24 listed API and CDMO Pharma stocks in India. The largest by market value are Divi's Lab (₹2.93 lakh crore), Laurus Labs (₹1.25 lakh crore), Gland Pharma (₹53,306 crore), Anthem Biosciences and Sai Life Sciences, at prices of 18 November 2026. 13 of the 24 companies we track are beating the Nifty 500 on share price over recent months.
API and CDMO Pharma: Divis Laboratories Ltd owns the largest revenue base; Neuland Laboratories Ltd has the fastest current growth.
The main question: the biggest companies are not always the ones changing the most.
Start with size. Then the direction of earnings. Then the quality of the business. A share price that leads means more once those three agree.
Our full read on API and CDMO Pharma companies, including what their managements promised and what could stop the run, is in the Sector Alpha newsletter.
How big is the API and CDMO Pharma sector?
There are 24 listed API and CDMO Pharma companies on this page, worth ₹8.1 lakh cr together at prices of 18 November 2026. Divi's Lab alone is ₹2.9 lakh cr, about 36% of the total.
Market values at prices of 18 November 2026.
What did API and CDMO Pharma managements say about July to September 2026?
13 of 13 Pharma - API & CRAMS companies held a results call for July to September 2026. Dishman Carbogen Amcis guided: FY27 no revenue growth expected as deferred orders shift to next year.
Dishman Carbogen Amcis call 16 November 2026
“Our consideration is if AI development continues slowing down, some shift of venture capital into some medical industry is expected.”Stephan Fritschi
Guided: FY27 no revenue growth expected as deferred orders shift to next year.
Innova Captab call 16 November 2026
“Abhi, if you see that the business model with 3 times the FATR and 15-16% EBITDA will also result in 16-17% ROE with 90 days of working capital, it is simple mathematics.”Management
Guided: Volume growth 20% in coming years with 2-year runway on existing assets and ₹400 crore treasury for greenfield or inorganic beyond FY29.
Divis Laboratories call 7 November 2026
“All I will say is that, with our futuristic capacity, we will be among the top three players.”Kiran S. Divi
Guided: FY27 revenue growth double-digit reiterated as forward path without pinning H2 pace.
Sai Life Sciences call 6 November 2026
“We believe that such integrated partnerships will help us build a robust, consistent, and predictable long-term pipeline and revenue base.”Krishna Kanumuri
Guided: H2 FY27 performance stronger than H1.
Windlas Biotech call 6 November 2026
“My instinct is to say that this is credit to the team rather than credit to API prices.”Hitesh Windlass
Guided: Company-level base can serve up to about ₹1,100 crore plus around 10% debottlenecking headroom.
Blue Jet Healthcare call 5 November 2026
“Our ambition is not simply to add manufacturing capacity. We are building a globally competitive CDMO platform that combines decades of complex chemistry expertise with integrated R&D, flexible manufacturing infrastructure, and long-standing relationships with global pharmaceutical innovators.”Shiven Arora
Guided: Mahad Unit 3 KSM backward-integration facility planned on stream in H2FY27, enabling full chain integration.
Anthem Biosciences call 4 November 2026
“We have further solidified our industry-leading margins and are well-positioned to sustain this performance for the whole year.”Ajay Bharadwaj
Guided: Double-digit revenue growth try for FY27 to offset slow Q1.
Hikal call 3 November 2026
“It is a pure CDMO niche molecule, and the EBITDA will be well in excess of the EBITDA margins of the company.”Sameer Hiremath
Guided: FY27 mid-teen revenue growth reiterated with H2 topline significantly stronger than H1.
5 more Pharma - API & CRAMS calls held for July to September 2026 are not shown here, to keep the page fast.
From the results calls for July to September 2026.
Is money moving into API and CDMO Pharma stocks? Who is adding capacity?
Big funds, foreign and Indian, raised their stake by 0.4 points over the last two quarters. Founders and promoters kept theirs about the same.
- Spending on new plants and equipment was ₹12,660 crore in the last 12 months, 27% more than a year before.
- Projects still being built grew 23% in a year.
- 2 Pharma - API & CRAMS calls in the last quarters talked about adding capacity.
Big funds = foreign and Indian institutions, change in their share of ownership across 26 Pharma - API & CRAMS companies, in percentage points.
Ownership and spending as of 10 October 2026.
What to watch next in API and CDMO Pharma stocks?
The next things that show whether the Pharma - API & CRAMS story is on course. First: Anthem's expected recovery in deliveries and plant use after its soft first quarter.
- Gland's constrained vial-line approval and contract conversion.
- Neuland's peptide commissioning and qualification after the revised schedule.
- Acutaas's commercial contribution from validated manufacturing products.
- Granules's expected peptide-business profitability in FY27.
- Shilpa's partner resubmission and clarification of delayed launch dates.
What would change the story
A next reported quarter in which combined profit falls below the same quarter a year earlier while operating margin also falls below that quarter's level would break the earnings-supported breakout call.
From our industry review of 10 October 2026.
Which are the biggest API and CDMO Pharma stocks in India?
The largest API and CDMO Pharma stocks in India by market value are Divi's Lab (₹2.93 lakh crore), Laurus Labs (₹1.25 lakh crore) and Gland Pharma (₹53,306 crore), at prices of 18 Nov 2026.
- Divi's Lab: ₹11,049 | market value ₹2.93 lakh crore | P/E 84.2
- Laurus Labs: ₹2,322.50 | market value ₹1.25 lakh crore | P/E 89.8
- Gland Pharma: ₹3,230.50 | market value ₹53,306 crore | P/E 41.8
- Anthem Biosciences: ₹914.35 | market value ₹51,522 crore | P/E 81.8
- Sai Life Sciences: ₹1,788.10 | market value ₹38,012 crore | P/E 93.4
- Acutaas Chemicals: ₹3,991.30 | market value ₹32,678 crore | P/E 73.5
- Piramal Pharma: ₹238.95 | market value ₹31,744 crore
- Neuland Laboratories: ₹21,455 | market value ₹27,527 crore | P/E 61.9
- Granules: ₹797.50 | market value ₹21,754 crore | P/E 27.7
- OneSource Specialty Pharma: ₹1,586.20 | market value ₹18,190 crore
The other 14 API and CDMO Pharma companies are in the full list below.
Share price | market value | P/E, biggest first. Prices, market values and ratios at the official close of 18 Nov 2026; the score list below uses the weekly figures.
Which are the API and CDMO Pharma stocks, ranked?
Ranked by the 4-Factor Sector Score (growth & earnings 35, capital efficiency 25, valuation 20, relative strength 20). The scores come from our weekly scan.
- 1Laurus Labs LtdLAURUSLABS · ₹1.3 lakh cr74.4of 100favourable · strongest on relative strength versus sector and ROCE improvement
- 2Acutaas Chemicals LtdACUTAAS · ₹32,700 cr74.1of 100favourable · strongest on ROCE and ROCE improvement
- 3Divis Laboratories LtdDIVISLAB · ₹2.9 lakh cr68.7of 100favourable · strongest on ROCE and margin improvement
- 4Gland Pharma LtdGLAND · ₹53,300 cr67.7of 100favourable · strongest on ROCE improvement and relative strength versus sector
- 5IOL Chemicals & Pharmaceuticals LtdIOLCP · ₹5,570 cr65.2of 100favourable · strongest on relative strength versus sector and ROCE improvement
- 6Neuland Laboratories LtdNEULANDLAB · ₹27,500 cr65.0of 100favourable · strongest on ROCE and ROCE improvement
- 7Shilpa Medicare LtdSHILPAMED · ₹17,900 cr64.1of 100mixed, leaning good · strongest on profit growth and relative strength versus sector
- 8Morepen Laboratories LtdMOREPENLAB · ₹5,060 cr63.4of 100mixed, leaning good · strongest on ROCE improvement and profit growth
- 9Sai Life Sciences LtdSAILIFE · ₹38,000 cr58.3of 100mixed, leaning good · strongest on relative strength versus sector and ROCE
- 10SMS Pharmaceuticals LtdSMSPHARMA · ₹4,470 cr56.0of 100mixed, leaning good · strongest on 13-week relative-strength change and profit growth
Is there a Nifty API and CDMO Pharma index, and what is in it?
The largest 15 of 24 listed Indian Pharma - API & CRAMS companies are named here; all 24 are ranked in the scorecard. This is the set of companies people mean when they search for a Nifty Pharma - API & CRAMS index; the exchange publishes its own indices only for the largest sectors, so this equal-weighted set stands in for one.
- Divis Laboratories Ltd₹2.9 lakh cr
- Laurus Labs Ltd₹1.3 lakh cr
- Gland Pharma Ltd₹53,300 cr
- Anthem Biosciences Ltd₹51,500 cr
- Sai Life Sciences Ltd₹38,000 cr
- Acutaas Chemicals Ltd₹32,700 cr
- Piramal Pharma Ltd₹31,700 cr
- Neuland Laboratories Ltd₹27,500 cr
- Granules India Ltd₹21,800 cr
- Shilpa Medicare Ltd₹17,900 cr
- OneSource Specialty Pharma Ltd₹18,200 cr
- Syngene International Ltd₹17,600 cr
- Cohance Lifesciences Ltd₹17,500 cr
- Jubilant Pharmova Ltd₹14,900 cr
- Concord Biotech Ltd₹11,700 cr
The remaining 9 Pharma - API & CRAMS companies are named and ranked in the scorecard.
How many API and CDMO Pharma companies are listed in India?
24 API and CDMO Pharma companies in the Pharma - API & CRAMS industry group have a page on Sector Alpha, and all 24 are listed below, largest first. The largest is Divis Laboratories (₹2.93 lakh crore) and the smallest with a market value is Dishman Carbogen Amcis.
| Company | Market value |
|---|---|
| 1. Divis Laboratories Ltd DIVISLAB | ₹2.93 lakh crore |
| 2. Laurus Labs Ltd LAURUSLABS | ₹1.25 lakh crore |
| 3. Gland Pharma Ltd GLAND | ₹53,306 crore |
| 4. Anthem Biosciences Ltd ANTHEM | ₹51,522 crore |
| 5. Sai Life Sciences Ltd SAILIFE | ₹38,012 crore |
| 6. Acutaas Chemicals Ltd ACUTAAS | ₹32,678 crore |
| 7. Piramal Pharma Ltd PPLPHARMA | ₹31,744 crore |
| 8. Neuland Laboratories Ltd NEULANDLAB | ₹27,527 crore |
| 9. Granules India Ltd GRANULES | ₹21,754 crore |
| 10. OneSource Specialty Pharma Ltd ONESOURCE | ₹18,190 crore |
| 11. Shilpa Medicare Ltd SHILPAMED | ₹17,902 crore |
| 12. Syngene International Ltd SYNGENE | ₹17,552 crore |
| 13. Cohance Lifesciences Ltd COHANCE | ₹17,463 crore |
| 14. Jubilant Pharmova Ltd JUBLPHARMA | ₹14,872 crore |
| 15. Concord Biotech Ltd CONCORDBIO | ₹11,738 crore |
| 16. Blue Jet Healthcare Ltd BLUEJET | ₹9,814 crore |
| 17. IOL Chemicals & Pharmaceuticals Ltd IOLCP | ₹5,569 crore |
| 18. Morepen Laboratories Ltd MOREPENLAB | ₹5,062 crore |
| 19. Supriya Lifescience Ltd SUPRIYA | ₹4,948 crore |
| 20. SMS Pharmaceuticals Ltd SMSPHARMA | ₹4,465 crore |
| 21. Solara Active Pharma Sciences Ltd SOLARA | ₹3,157 crore |
| 22. Hikal Ltd HIKAL | ₹2,751 crore |
| 23. Windlas Biotech Ltd WINDLAS | ₹2,041 crore |
| 24. Dishman Carbogen Amcis Ltd DCAL | ₹1,899 crore |
How have API and CDMO Pharma stocks moved against NIFTY 500?
The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the last two years (104 weeks) this sector is 36% ahead of NIFTY 500. Earnings across its companies grew 17% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 34 weeks running.
Price and the fundamentals both up. 13 of 24 companies pass the momentum test (5+ points ahead of the Nifty 500 over 3 months, within 20% of the 52-week high).
Ahead of NIFTY 500 on the three-month view for 34 weeks running; 21 of the 24 companies in the industry index above their 200-day average (1 more than four weeks earlier); 13 of those 24 pass the momentum test (no change from four weeks earlier); earnings rising at 13 of the 24 that report earnings.
Ahead of NIFTY 500 for 34 weeks running and +39.4% over a year, with 13 → 13 of 24 stocks participating. Earnings mixed, 13 of 24 members have higher trailing twelve-month earnings than a year ago.
1Y
Pharma - API & CRAMS against NIFTY 500
Both lines start at 200 in the first week shown
- API and CDMO Pharma 288
- NIFTY 500 200
| Week ending | API and CDMO Pharma | NIFTY 500 |
|---|---|---|
| 21 Nov 2025 | 200 | 200 |
| 28 Nov 2025 | 203 | 201 |
| 5 Dec 2025 | 200 | 200 |
| 12 Dec 2025 | 200 | 199 |
| 19 Dec 2025 | 200 | 199 |
| 26 Dec 2025 | 200 | 200 |
| 2 Jan 2026 | 202 | 203 |
| 9 Jan 2026 | 196 | 197 |
| 16 Jan 2026 | 193 | 197 |
| 23 Jan 2026 | 178 | 191 |
| 30 Jan 2026 | 178 | 194 |
| 6 Feb 2026 | 179 | 197 |
| 13 Feb 2026 | 182 | 196 |
| 20 Feb 2026 | 181 | 197 |
| 27 Feb 2026 | 184 | 195 |
| 6 Mar 2026 | 179 | 189 |
| 13 Mar 2026 | 174 | 180 |
| 20 Mar 2026 | 176 | 179 |
| 27 Mar 2026 | 178 | 177 |
| 3 Apr 2026 | 177 | 176 |
| 10 Apr 2026 | 190 | 188 |
| 17 Apr 2026 | 196 | 192 |
| 24 Apr 2026 | 195 | 190 |
| 1 May 2026 | 205 | 191 |
| 8 May 2026 | 217 | 194 |
| 15 May 2026 | 214 | 189 |
| 22 May 2026 | 221 | 190 |
| 29 May 2026 | 223 | 190 |
| 5 Jun 2026 | 226 | 189 |
| 12 Jun 2026 | 230 | 190 |
| 19 Jun 2026 | 228 | 195 |
| 26 Jun 2026 | 232 | 194 |
| 3 Jul 2026 | 244 | 196 |
| 10 Jul 2026 | 245 | 196 |
| 17 Jul 2026 | 243 | 196 |
| 24 Jul 2026 | 236 | 193 |
| 31 Jul 2026 | 242 | 197 |
| 7 Aug 2026 | 256 | 199 |
| 14 Aug 2026 | 257 | 198 |
| 21 Aug 2026 | 262 | 198 |
| 28 Aug 2026 | 267 | 198 |
| 4 Sep 2026 | 272 | 195 |
| 11 Sep 2026 | 280 | 192 |
| 18 Sep 2026 | 281 | 192 |
| 25 Sep 2026 | 281 | 190 |
| 2 Oct 2026 | 273 | 184 |
| 9 Oct 2026 | 266 | 184 |
| 16 Oct 2026 | 266 | 187 |
| 23 Oct 2026 | 252 | 180 |
| 30 Oct 2026 | 275 | 184 |
| 6 Nov 2026 | 282 | 197 |
| 13 Nov 2026 | 288 | 200 |
3Y
Pharma - API & CRAMS against NIFTY 500
Both lines start at 200 in the first week shown, every 2nd week shown
- API and CDMO Pharma 516
- NIFTY 500 269
| Week ending | API and CDMO Pharma | NIFTY 500 |
|---|---|---|
| 24 Nov 2023 | 200 | 200 |
| 1 Dec 2023 | 202 | 205 |
| 15 Dec 2023 | 203 | 217 |
| 29 Dec 2023 | 212 | 220 |
| 12 Jan 2024 | 219 | 224 |
| 26 Jan 2024 | 211 | 220 |
| 9 Feb 2024 | 220 | 226 |
| 23 Feb 2024 | 229 | 230 |
| 8 Mar 2024 | 226 | 232 |
| 22 Mar 2024 | 221 | 227 |
| 5 Apr 2024 | 237 | 235 |
| 19 Apr 2024 | 240 | 231 |
| 3 May 2024 | 244 | 238 |
| 17 May 2024 | 238 | 239 |
| 31 May 2024 | 233 | 239 |
| 14 Jun 2024 | 252 | 252 |
| 28 Jun 2024 | 260 | 256 |
| 12 Jul 2024 | 273 | 262 |
| 26 Jul 2024 | 281 | 264 |
| 9 Aug 2024 | 298 | 260 |
| 23 Aug 2024 | 315 | 265 |
| 6 Sep 2024 | 338 | 266 |
| 20 Sep 2024 | 354 | 274 |
| 4 Oct 2024 | 340 | 267 |
| 18 Oct 2024 | 350 | 266 |
| 1 Nov 2024 | 361 | 259 |
| 15 Nov 2024 | 359 | 249 |
| 29 Nov 2024 | 383 | 257 |
| 13 Dec 2024 | 374 | 265 |
| 27 Dec 2024 | 368 | 254 |
| 10 Jan 2025 | 358 | 247 |
| 24 Jan 2025 | 344 | 242 |
| 7 Feb 2025 | 362 | 245 |
| 21 Feb 2025 | 326 | 235 |
| 7 Mar 2025 | 333 | 232 |
| 21 Mar 2025 | 346 | 241 |
| 4 Apr 2025 | 331 | 236 |
| 18 Apr 2025 | 344 | 246 |
| 2 May 2025 | 332 | 249 |
| 16 May 2025 | 343 | 259 |
| 30 May 2025 | 366 | 258 |
| 13 Jun 2025 | 373 | 260 |
| 27 Jun 2025 | 371 | 268 |
| 11 Jul 2025 | 373 | 264 |
| 25 Jul 2025 | 381 | 261 |
| 8 Aug 2025 | 361 | 254 |
| 22 Aug 2025 | 376 | 261 |
| 5 Sep 2025 | 378 | 259 |
| 19 Sep 2025 | 394 | 266 |
| 3 Oct 2025 | 376 | 261 |
| 17 Oct 2025 | 381 | 268 |
| 31 Oct 2025 | 382 | 269 |
| 14 Nov 2025 | 372 | 270 |
| 28 Nov 2025 | 362 | 271 |
| 12 Dec 2025 | 359 | 269 |
| 26 Dec 2025 | 357 | 270 |
| 9 Jan 2026 | 351 | 266 |
| 23 Jan 2026 | 319 | 257 |
| 6 Feb 2026 | 321 | 266 |
| 20 Feb 2026 | 324 | 265 |
| 6 Mar 2026 | 321 | 255 |
| 20 Mar 2026 | 315 | 242 |
| 3 Apr 2026 | 316 | 237 |
| 17 Apr 2026 | 351 | 259 |
| 1 May 2026 | 367 | 257 |
| 15 May 2026 | 383 | 255 |
| 29 May 2026 | 399 | 257 |
| 12 Jun 2026 | 411 | 256 |
| 26 Jun 2026 | 415 | 262 |
| 10 Jul 2026 | 438 | 265 |
| 24 Jul 2026 | 422 | 260 |
| 7 Aug 2026 | 459 | 269 |
| 21 Aug 2026 | 469 | 267 |
| 4 Sep 2026 | 486 | 264 |
| 18 Sep 2026 | 502 | 259 |
| 2 Oct 2026 | 489 | 248 |
| 16 Oct 2026 | 476 | 252 |
| 30 Oct 2026 | 493 | 248 |
| 13 Nov 2026 | 516 | 269 |
5Y
Pharma - API & CRAMS against NIFTY 500
Both lines start at 200 in the first week shown, every 4th week shown
- API and CDMO Pharma 505
- NIFTY 500 323
| Week ending | API and CDMO Pharma | NIFTY 500 |
|---|---|---|
| 26 Nov 2021 | 200 | 200 |
| 17 Dec 2021 | 194 | 200 |
| 14 Jan 2022 | 207 | 214 |
| 11 Feb 2022 | 180 | 203 |
| 11 Mar 2022 | 175 | 194 |
| 8 Apr 2022 | 192 | 209 |
| 6 May 2022 | 172 | 192 |
| 3 Jun 2022 | 155 | 191 |
| 1 Jul 2022 | 148 | 182 |
| 29 Jul 2022 | 156 | 199 |
| 26 Aug 2022 | 158 | 206 |
| 23 Sep 2022 | 155 | 205 |
| 21 Oct 2022 | 151 | 205 |
| 18 Nov 2022 | 150 | 211 |
| 16 Dec 2022 | 149 | 213 |
| 13 Jan 2023 | 148 | 209 |
| 10 Feb 2023 | 134 | 204 |
| 10 Mar 2023 | 135 | 200 |
| 7 Apr 2023 | 136 | 201 |
| 5 May 2023 | 146 | 208 |
| 2 Jun 2023 | 154 | 215 |
| 30 Jun 2023 | 164 | 223 |
| 28 Jul 2023 | 173 | 230 |
| 25 Aug 2023 | 184 | 229 |
| 22 Sep 2023 | 187 | 235 |
| 20 Oct 2023 | 183 | 234 |
| 17 Nov 2023 | 191 | 239 |
| 15 Dec 2023 | 198 | 260 |
| 12 Jan 2024 | 214 | 269 |
| 9 Feb 2024 | 215 | 271 |
| 8 Mar 2024 | 221 | 278 |
| 5 Apr 2024 | 232 | 282 |
| 3 May 2024 | 238 | 285 |
| 31 May 2024 | 228 | 287 |
| 28 Jun 2024 | 255 | 307 |
| 26 Jul 2024 | 275 | 317 |
| 23 Aug 2024 | 308 | 318 |
| 20 Sep 2024 | 346 | 329 |
| 18 Oct 2024 | 343 | 319 |
| 15 Nov 2024 | 351 | 299 |
| 13 Dec 2024 | 366 | 318 |
| 10 Jan 2025 | 350 | 296 |
| 7 Feb 2025 | 354 | 294 |
| 7 Mar 2025 | 326 | 278 |
| 4 Apr 2025 | 324 | 283 |
| 2 May 2025 | 324 | 299 |
| 30 May 2025 | 358 | 310 |
| 27 Jun 2025 | 363 | 321 |
| 25 Jul 2025 | 372 | 313 |
| 22 Aug 2025 | 368 | 313 |
| 19 Sep 2025 | 386 | 319 |
| 17 Oct 2025 | 372 | 321 |
| 14 Nov 2025 | 363 | 324 |
| 12 Dec 2025 | 351 | 323 |
| 9 Jan 2026 | 344 | 319 |
| 6 Feb 2026 | 314 | 319 |
| 6 Mar 2026 | 314 | 306 |
| 3 Apr 2026 | 309 | 285 |
| 1 May 2026 | 359 | 308 |
| 29 May 2026 | 391 | 308 |
| 26 Jun 2026 | 406 | 314 |
| 24 Jul 2026 | 412 | 312 |
| 21 Aug 2026 | 458 | 320 |
| 18 Sep 2026 | 491 | 311 |
| 16 Oct 2026 | 466 | 303 |
| 13 Nov 2026 | 505 | 323 |
Earnings, each company rebased to 100, the sector takes the median
Latest quarter July to September 2026: 144.6, from 21 companies
| Quarter | Median earnings index |
|---|---|
| Apr 2022 | 100.0 (13 companies) |
| Jul 2022 | 88.9 (15 companies) |
| Oct 2022 | 76.9 (15 companies) |
| Jan 2023 | 71.5 (15 companies) |
| Apr 2023 | 68.3 (17 companies) |
| Jul 2023 | 83.3 (19 companies) |
| Oct 2023 | 85.9 (19 companies) |
| Jan 2024 | 77.3 (19 companies) |
| Apr 2024 | 77.2 (19 companies) |
| Jul 2024 | 94.4 (20 companies) |
| Oct 2024 | 103.5 (20 companies) |
| Jan 2025 | 112.8 (21 companies) |
| Apr 2025 | 102.9 (21 companies) |
| Jul 2025 | 108.2 (21 companies) |
| Oct 2025 | 107.1 (21 companies) |
| Jan 2026 | 119.3 (21 companies) |
| Apr 2026 | 127.0 (21 companies) |
| Jul 2026 | 144.6 (21 companies) |
Both lines start at 200 in the same week, so the gap between them tells the story: the sector line is an equal-weighted index of its 24 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member set to 100 at the start and the sector taking the middle value, so a price line pulling away from flat bars means the market is paying more for the same earnings. A bar turns grey when that figure is lower than the quarter before. The rules are fixed and the same everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover or tap any point to read both values and the gap.
Are API and CDMO Pharma stocks outperforming NIFTY 500?
Pharma - API & CRAMS has done better than the NIFTY 500 by 34.7% over the last 52 weeks. Over 13 weeks the gap is a lead of 11.8%. Shilpa Medicare Ltd is the strongest against the sector itself at +43.4%. Readings are as of 13 November 2026.
Relative-strength score for the industry: 19.2 as of 13 November 2026 (leaders, rising).
What is the bottom line on API and CDMO Pharma stocks?
Pharma - API & CRAMS has done better than the NIFTY 500 by 34.7% over 52 weeks and by 11.8% over 13 weeks. 13 of 24 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months), and 8 of the 18 with a long enough price history are ahead of the industry itself.
How does each API and CDMO Pharma stock score?
A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.
Laurus Labs Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 93% evidence confidence.
Blue Jet Healthcare Ltd scores well on valuation against its peers or its own history, but its earnings have not yet improved enough to back that up.
- 1Laurus Labs LtdLAURUSLABS · leader · favourable · 93% evidence74.4out of 100
How the score adds up
Growth & earnings 32.2/35 · Revenue 23% · PAT 95.3% · OPM change 10 pp · 100% evidenceCapital efficiency 17.4/25 · ROCE 17.8% (year to Mar 2026) · OPM 34% · 100% evidenceValuation 7.1/20 · P/E 93.7× · PEG 2.27 · 65% evidenceRelative strength 17.7/20 · RS sector 35.5% · RS bench 63.4% · 1Y 137.4% · 100% evidence · 12 of 12 weeks aheadExact sum: 32.2 + 17.4 + 7.1 + 17.7 = 74.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 2Acutaas Chemicals LtdACUTAAS · turning · favourable · 67% evidence74.1out of 100
How the score adds up
Growth & earnings 32.0/35 · Revenue 45.4% · PAT 95.5% · OPM change 9 pp · 95% evidenceCapital efficiency 20.2/25 · ROCE 31.6% (year to Mar 2026) · OPM 40.3% · 76% evidenceValuation 10.4/20 · P/E 74.4× · PEG — · 50% evidenceRelative strength 11.5/20 · RS sector — · RS bench 43.7% · 1Y 134.5% · 25% evidence · 3 of 9 weeks aheadExact sum: 32 + 20.2 + 10.4 + 11.5 = 74.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 3Divis Laboratories LtdDIVISLAB · leader · favourable · 100% evidence68.7out of 100
How the score adds up
Growth & earnings 28.6/35 · Revenue 21.6% · PAT 35.3% · OPM change 10 pp · 100% evidenceCapital efficiency 19.6/25 · ROCE 22% (year to Mar 2026) · OPM 42.6% · 100% evidenceValuation 3.0/20 · P/E 87.2× · PEG 2.88 · 100% evidenceRelative strength 17.5/20 · RS sector 22.7% · RS bench 50.5% · 1Y 73.4% · 100% evidence · 12 of 12 weeks aheadExact sum: 28.6 + 19.6 + 3 + 17.5 = 68.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 4Gland Pharma LtdGLAND · leader · favourable · 100% evidence67.7out of 100
How the score adds up
Growth & earnings 28.1/35 · Revenue 21.9% · PAT 56.3% · OPM change 5 pp · 100% evidenceCapital efficiency 17.1/25 · ROCE 15.1% (year to Mar 2026) · OPM 26.4% · 100% evidenceValuation 10.2/20 · P/E 43.1× · PEG 1.84 · 100% evidenceRelative strength 12.3/20 · RS sector 18.8% · RS bench 44.6% · 1Y 78.5% · 100% evidence · 12 of 12 weeks aheadExact sum: 28.1 + 17.1 + 10.2 + 12.3 = 67.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 5IOL Chemicals & Pharmaceuticals LtdIOLCP · leader · favourable · 90% evidence65.2out of 100
How the score adds up
Growth & earnings 29.2/35 · Revenue 26.7% · PAT 75% · OPM change 4 pp · 100% evidenceCapital efficiency 12.7/25 · ROCE 11.3% (year to Mar 2026) · OPM 13.7% · 100% evidenceValuation 9.3/20 · P/E 27.4× · PEG — · 50% evidenceRelative strength 14.0/20 · RS sector 30.8% · RS bench 55.8% · 1Y 110.1% · 100% evidence · 12 of 12 weeks aheadExact sum: 29.2 + 12.7 + 9.3 + 14 = 65.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 6Neuland Laboratories LtdNEULANDLAB · fading · favourable · 100% evidence65.0out of 100
How the score adds up
Growth & earnings 26.7/35 · Revenue 50.5% · PAT 88.4% · OPM change −8 pp · 100% evidenceCapital efficiency 21.9/25 · ROCE 26.5% (year to Mar 2026) · OPM 21.8% · 100% evidenceValuation 10.0/20 · P/E 60.8× · PEG 1.91 · 100% evidenceRelative strength 6.4/20 · RS sector −3.9% · RS bench 17.8% · 1Y 29.3% · 100% evidence · 10 of 12 weeks aheadExact sum: 26.7 + 21.9 + 10 + 6.4 = 65 · What this means: Earnings are strong; relative strength in its sector is −3.9% and the one-year return is 29.3%. - 7Shilpa Medicare LtdSHILPAMED · leader · mixed, leaning good · 93% evidence64.1out of 100
How the score adds up
Growth & earnings 24.6/35 · Revenue 37.4% · PAT 100% · OPM change −2 pp · 100% evidenceCapital efficiency 12.2/25 · ROCE 10.9% (year to Mar 2026) · OPM 26.8% · 100% evidenceValuation 12.6/20 · P/E 53.8× · PEG 1.42 · 65% evidenceRelative strength 14.7/20 · RS sector 43.4% · RS bench 69% · 1Y 161.1% · 100% evidence · 12 of 12 weeks aheadExact sum: 24.6 + 12.2 + 12.6 + 14.7 = 64.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 8Morepen Laboratories LtdMOREPENLAB · leader · mixed, leaning good · 75% evidence63.4out of 100
How the score adds up
Growth & earnings 31.8/35 · Revenue 30.1% · PAT 90.9% · OPM change 9 pp · 100% evidenceCapital efficiency 9.3/25 · ROCE 8.1% (year to Mar 2026) · OPM 16.5% · 100% evidenceValuation 10.4/20 · P/E 26.9× · PEG — · 50% evidenceRelative strength 11.9/20 · RS sector — · RS bench 52.4% · 1Y 109.9% · 25% evidence · 12 of 12 weeks aheadExact sum: 31.8 + 9.3 + 10.4 + 11.9 = 63.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 9Sai Life Sciences LtdSAILIFE · leader · mixed, leaning good · 93% evidence58.3out of 100
How the score adds up
Growth & earnings 20.2/35 · Revenue 15.5% · PAT 31.1% · OPM change 1 pp · 100% evidenceCapital efficiency 15.8/25 · ROCE 19.6% (year to Mar 2026) · OPM 28.2% · 100% evidenceValuation 4.5/20 · P/E 100.7× · PEG 3.55 · 65% evidenceRelative strength 17.8/20 · RS sector 29.5% · RS bench 57.9% · 1Y 107.6% · 100% evidence · 12 of 12 weeks aheadExact sum: 20.2 + 15.8 + 4.5 + 17.8 = 58.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 10SMS Pharmaceuticals LtdSMSPHARMA · breaking out · mixed, leaning good · 90% evidence56.0out of 100
How the score adds up
Growth & earnings 20.5/35 · Revenue 13% · PAT 41% · OPM change 1 pp · 100% evidenceCapital efficiency 11.9/25 · ROCE 13.3% (year to Mar 2026) · OPM 21.5% · 100% evidenceValuation 8.3/20 · P/E 38.2× · PEG — · 50% evidenceRelative strength 15.3/20 · RS sector 2.4% · RS bench 27.1% · 1Y 69.1% · 100% evidence · 10 of 12 weeks aheadExact sum: 20.5 + 11.9 + 8.3 + 15.3 = 56 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 11Anthem Biosciences LtdANTHEM · fading · mixed, leaning good · 93% evidence53.0out of 100
- 12Windlas Biotech LtdWINDLAS · fading · mixed, leaning good · 75% evidence52.6out of 100
- 13Granules India LtdGRANULES · quiet · mixed, leaning good · 100% evidence51.8out of 100
- 14Solara Active Pharma Sciences LtdSOLARA · leader · mixed, leaning good · 74% evidence50.2out of 100
- 15Blue Jet Healthcare LtdBLUEJET · quiet · mixed, leaning weak · 85% evidence48.9out of 100
- 16Concord Biotech LtdCONCORDBIO · quiet · mixed, leaning weak · 85% evidence46.1out of 100
- 17Piramal Pharma LtdPPLPHARMA · leader · mixed, leaning weak · 71% evidence44.0out of 100
- 18Hikal LtdHIKAL · turning · mixed, leaning weak · 78% evidence40.1out of 100
- 19Supriya Lifescience LtdSUPRIYA · quiet · mixed, leaning weak · 100% evidence39.1out of 100
- 20OneSource Specialty Pharma LtdONESOURCE · turning · weak · 80% evidence30.9out of 100
- 21Jubilant Pharmova LtdJUBLPHARMA · turning · weak · 90% evidence30.8out of 100
- 22Cohance Lifesciences LtdCOHANCE · fading · weak · 82% evidence24.9out of 100
- 23Dishman Carbogen Amcis LtdDCAL · basing · weak · 68% evidence24.8out of 100
- 24Syngene International LtdSYNGENE · turning · weak · 100% evidence24.5out of 100
How this score is built, and what the marks mean
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
How have API and CDMO Pharma share prices moved?
Shilpa Medicare Ltd has the strongest one-year price move in Pharma - API & CRAMS at +161.1%. It also leads on relative strength against the NIFTY, at +69.0%. 18 of 24 companies we track are ahead of the index on that measure. Every line covers 314 weekly closes through 13 November 2026.
Price and relative strength
Price · same starting point: Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
RS vs NIFTY 500: How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
RS vs sector: The same measure taken against Pharma - API & CRAMS itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
Biggest one-year moves
- 1Shilpa Medicare LtdSHILPAMED · ₹17,900 cr+161.1%1 year
- 2Laurus Labs LtdLAURUSLABS · ₹1.3 lakh cr+137.4%1 year
- 3Acutaas Chemicals LtdACUTAAS · ₹32,700 cr+134.5%1 year
- 4IOL Chemicals & Pharmaceuticals LtdIOLCP · ₹5,570 cr+110.1%1 year
- 5Morepen Laboratories LtdMOREPENLAB · ₹5,060 cr+109.9%1 year
Strongest against NIFTY 500
- 1Shilpa Medicare LtdSHILPAMED · ₹17,900 cr+69.0%vs NIFTY 500
- 2Laurus Labs LtdLAURUSLABS · ₹1.3 lakh cr+63.4%vs NIFTY 500
- 3Sai Life Sciences LtdSAILIFE · ₹38,000 cr+57.9%vs NIFTY 500
- 4IOL Chemicals & Pharmaceuticals LtdIOLCP · ₹5,570 cr+55.8%vs NIFTY 500
- 5Morepen Laboratories LtdMOREPENLAB · ₹5,060 cr+52.4%vs NIFTY 500
Strongest against the sector itself
- 1Shilpa Medicare LtdSHILPAMED · ₹17,900 cr+43.4%vs sector
- 2Laurus Labs LtdLAURUSLABS · ₹1.3 lakh cr+35.5%vs sector
- 3IOL Chemicals & Pharmaceuticals LtdIOLCP · ₹5,570 cr+30.8%vs sector
- 4Sai Life Sciences LtdSAILIFE · ₹38,000 cr+29.5%vs sector
- 5Divis Laboratories LtdDIVISLAB · ₹2.9 lakh cr+22.7%vs sector
Why are API and CDMO Pharma stocks moving?
The monthly price and earnings indices began near 84.2 and 100.2 in December 2016; by December 2019, prices were 112.5 while earnings were still 84. Prices then surged to 358.6 by September 2021, alongside earnings of 140.9, before falling to 188.7 by March 2023. In the week of 5 October 2026, 87.5% of 24 Pharma - API & CRAMS companies were beating the Nifty 500, against 52.2% on 25 May 2026.
Pharma - API & CRAMS is one of the Top 25 sectors in our latest review.
Pharma - API & CRAMS: share of companies beating the Nifty 500, and above their 200-day average, to 5 October 2026, last sector review
- Beating the Nifty 500 87.5%
- Above the 200-day average 66.7%
| Week | Beating the Nifty 500 | Above the 200-day average |
|---|---|---|
| 25 May 2026 | 52.2% | 66.7% |
| 1 Jun 2026 | 52.2% | 58.3% |
| 8 Jun 2026 | 56.5% | 66.7% |
| 15 Jun 2026 | 56.5% | 66.7% |
| 22 Jun 2026 | 60.9% | 66.7% |
| 29 Jun 2026 | 60.9% | 75% |
| 6 Jul 2026 | 65.2% | 70.8% |
| 13 Jul 2026 | 75% | 87.5% |
| 20 Jul 2026 | 70.8% | 70.8% |
| 27 Jul 2026 | 66.7% | 70.8% |
| 3 Aug 2026 | 75% | 75% |
| 10 Aug 2026 | 70.8% | 70.8% |
| 17 Aug 2026 | 75% | 70.8% |
| 24 Aug 2026 | 75% | 70.8% |
| 31 Aug 2026 | 79.2% | 79.2% |
| 7 Sep 2026 | 83.3% | 83.3% |
| 14 Sep 2026 | 83.3% | 83.3% |
| 21 Sep 2026 | 87.5% | 79.2% |
| 28 Sep 2026 | 87.5% | 75% |
| 5 Oct 2026 | 87.5% | 66.7% |
Each week, the share of Pharma - API &
From our industry review of 10 October 2026.
What is changing for API and CDMO Pharma companies?
Customer contracts and new products provide further growth, but approvals and delivery dates remain uncertain.
| What is changing | Which companies | Lasting? |
|---|---|---|
| Higher-value products and a better mix | Divi's, Laurus, Gland, Acutaas, Granules and Shilpa describe a shift toward more differentiated work or products. | looks lasting |
| A bigger order book | looks lasting | |
| Costs spread over more sales | Laurus, Gland, Piramal and Acutaas report benefits from higher sales or better plant use. | may be cyclical |
| More business from existing customers | Sai Life describes expanding integrated customer programmes; Gland's driver read records growth from existing customers. | too early to call |
| New products | Gland has an established launch stream, Divi's has commercial contrast-media supply, and Acutaas describes additional validated products. | too early to call |
| A bigger market to serve | Gland, Sai Life, Laurus and Granules are building capabilities for peptides or other complex therapies. | too early to call |
From our industry review of 10 October 2026.
Which other industries affect API and CDMO Pharma stocks?
1 chain of cause and effect links Pharma - API & CRAMS to other industries right now. Drug profits favour complex contracted work over undifferentiated ingredients. For Pharma - API & CRAMS: Complex products, customer commitments and better plant use support earnings.
Drug profits favour complex contracted work over undifferentiated ingredients helps Pharma - API & CRAMS
What started it: The previous assessment of calls from July 27 to August 14, 2026 reported higher gross margins at 9 of 10 Pharma - API & CRAMS companies and 19% growth in Indian contract drug research and manufacturing. The October 10 verdicts provide further company evidence, but no updated industry growth percentage.
For Pharma - API & CRAMS: Complex products, customer commitments and better plant use support earnings.
Also affected: Speciality Chemicals (helps), Pharma - API (hurts), Pharma - Formulators (hurts)
✓ fact Evidence: high.
From our cross-industry review of 10 October 2026.
Which API and CDMO Pharma companies have the most revenue, and which grow fastest?
Divis Laboratories Ltd has the highest Revenue among the 24 Pharma - API & CRAMS companies compared here, at ₹12,191 crore. Piramal Pharma Ltd is next at ₹9,779 crore. Neuland Laboratories Ltd has the highest Revenue growth at 50.5%, so level and change sit with different companies. 24 of 24 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: Divis Laboratories Ltd is the largest at ₹12,191 crore, 24.7% ahead of Piramal Pharma Ltd. Neuland Laboratories Ltd's growth is 50.5% from a ₹2,308 crore base, with 20 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.
What this means: Divis Laboratories Ltd is the size to compare against; Neuland Laboratories Ltd is the one growing fastest. The faster grower has to keep that growth and turn it into margin and returns before it counts as more than a fast start.
This conclusion weakens if: Divis Laboratories Ltd's growth falls below Neuland Laboratories Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenue · company comparison
Revenue · largest
- 1Divis Laboratories LtdDIVISLAB₹12,200 cr
- 2Piramal Pharma LtdPPLPHARMA₹9,780 cr
- 3Jubilant Pharmova LtdJUBLPHARMA₹9,010 cr
- 4Laurus Labs LtdLAURUSLABS₹7,820 cr
- 5Gland Pharma LtdGLAND₹7,070 cr
Revenue growth · fastest growers
- 1Neuland Laboratories LtdNEULANDLAB51%
- 2Acutaas Chemicals LtdACUTAAS45%
- 3Shilpa Medicare LtdSHILPAMED37%
- 4Morepen Laboratories LtdMOREPENLAB30%
- 5Solara Active Pharma Sciences LtdSOLARA27%
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Divis Laboratories Ltd DIVISLAB | ₹3,680 cr | 35% | Sep 2026 |
| Piramal Pharma Ltd PPLPHARMA | ₹2,620 cr | 28% | Sep 2026 |
| Jubilant Pharmova Ltd JUBLPHARMA | ₹2,370 cr | 21% | Sep 2026 |
| Laurus Labs Ltd LAURUSLABS | ₹2,210 cr | 33% | Sep 2026 |
| Gland Pharma Ltd GLAND | ₹1,830 cr | 23% | Sep 2026 |
| Granules India Ltd GRANULES | ₹1,560 cr | 20% | Sep 2026 |
| Syngene International Ltd SYNGENE | ₹833 cr | −8.6% | Sep 2026 |
| IOL Chemicals & Pharmaceuticals Ltd IOLCP | ₹795 cr | 40% | Sep 2026 |
| Morepen Laboratories Ltd MOREPENLAB | ₹746 cr | 81% | Sep 2026 |
| Sai Life Sciences Ltd SAILIFE | ₹659 cr | 23% | Sep 2026 |
| Anthem Biosciences Ltd ANTHEM | ₹594 cr | 8.0% | Sep 2026 |
| Shilpa Medicare Ltd SHILPAMED | ₹529 cr | 43% | Sep 2026 |
| OneSource Specialty Pharma Ltd ONESOURCE | ₹516 cr | 37% | Sep 2026 |
| Dishman Carbogen Amcis Ltd DCAL | ₹507 cr | −22% | Sep 2026 |
| Cohance Lifesciences Ltd COHANCE | ₹477 cr | −14% | Sep 2026 |
| Neuland Laboratories Ltd NEULANDLAB | ₹450 cr | −12% | Sep 2026 |
| Acutaas Chemicals Ltd ACUTAAS | ₹437 cr | 43% | Sep 2026 |
| Hikal Ltd HIKAL | ₹434 cr | 36% | Sep 2026 |
| Solara Active Pharma Sciences Ltd SOLARA | ₹417 cr | 33% | Sep 2026 |
| Blue Jet Healthcare Ltd BLUEJET | ₹376 cr | 128% | Sep 2026 |
| SMS Pharmaceuticals Ltd SMSPHARMA | ₹316 cr | 31% | Sep 2026 |
| Concord Biotech Ltd CONCORDBIO | ₹309 cr | 25% | Sep 2026 |
| Windlas Biotech Ltd WINDLAS | ₹264 cr | 19% | Sep 2026 |
| Supriya Lifescience Ltd SUPRIYA | ₹206 cr | 3.0% | Sep 2026 |
Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.
What to watch
Watch the next two reported quarters for growth persistence, margin conversion and whether the leader is gaining share without stretching working capital.
Which API and CDMO Pharma companies keep the most from each ₹100 of sales?
Anthem Biosciences Ltd has the highest OPM among the 24 Pharma - API & CRAMS companies compared here, at 45.6%. Divis Laboratories Ltd is next at 42.6%. Divis Laboratories Ltd has the highest Margin change at +10 percentage points, so level and change sit with different companies. 24 of 24 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: Anthem Biosciences Ltd leads opm at 45.6%; Divis Laboratories Ltd leads margin change at +10 percentage points.
What this means: Anthem Biosciences Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
Operating margin · company comparison
OPM, by reported quarter
- Anthem Biosciences 46%
- Divis Laboratories 43%
- Acutaas Chemicals 40%
- Laurus Labs 34%
- Concord Biotech 34%
| Quarter | Anthem Biosciences | Divis Laboratories | Acutaas Chemicals | Laurus Labs | Concord Biotech |
|---|---|---|---|---|---|
| Dec 2021 | — | 44% | 21% | 28% | — |
| Mar 2022 | — | 44% | 18% | 28% | — |
| Jun 2022 | — | 38% | 17% | 30% | 36% |
| Sep 2022 | — | 33% | 19% | 28% | 24% |
| Dec 2022 | — | 24% | 20% | 26% | 46% |
| Mar 2023 | — | 25% | 22% | 21% | 47% |
| Jun 2023 | 30% | 28% | 22% | 14% | 37% |
| Sep 2023 | 30% | 25% | 14% | 15% | 44% |
| Dec 2023 | 30% | 26% | 16% | 15% | 44% |
| Mar 2024 | 30% | 32% | 19% | 17% | 41% |
| Jun 2024 | 36% | 29% | 17% | 14% | 38% |
| Sep 2024 | 37% | 31% | 20% | 15% | 43% |
| Dec 2024 | 32% | 32% | 25% | 20% | 40% |
| Mar 2025 | 40% | 34% | 28% | 24% | 44% |
| Jun 2025 | 35% | 30% | 25% | 24% | 30% |
| Sep 2025 | 40% | 33% | 31% | 24% | 36% |
| Dec 2025 | 37% | 34% | 38% | 27% | 35% |
| Mar 2026 | 44% | 33% | 42% | 28% | 36% |
| Jun 2026 | 36% | 41% | 34% | 32% | 32% |
| Sep 2026 | 46% | 43% | 40% | 34% | 34% |
Margin change, by reported quarter
- Anthem Biosciences +6.0 pp
- Divis Laboratories +10.0 pp
- Acutaas Chemicals +9.0 pp
- Laurus Labs +10.0 pp
- Concord Biotech −2.0 pp
| Quarter | Anthem Biosciences | Divis Laboratories | Acutaas Chemicals | Laurus Labs | Concord Biotech |
|---|---|---|---|---|---|
| Dec 2021 | — | +3.4 pp | −2.4 pp | −5.4 pp | — |
| Mar 2022 | — | +3.8 pp | −7.1 pp | −5.6 pp | — |
| Jun 2022 | — | −5.8 pp | −2.0 pp | −1.4 pp | — |
| Sep 2022 | — | −7.7 pp | −3.2 pp | −0.2 pp | — |
| Dec 2022 | — | −20.0 pp | −1.2 pp | −1.7 pp | — |
| Mar 2023 | — | −18.9 pp | +4.0 pp | −6.8 pp | — |
| Jun 2023 | — | −9.7 pp | +4.5 pp | −15.5 pp | +1.3 pp |
| Sep 2023 | — | −8.5 pp | −5.1 pp | −13.5 pp | +20.4 pp |
| Dec 2023 | — | +2.0 pp | −4.0 pp | −11.0 pp | −2.0 pp |
| Mar 2024 | — | +7.0 pp | −3.0 pp | −4.0 pp | −6.0 pp |
| Jun 2024 | +5.6 pp | +1.0 pp | −5.0 pp | 0.0 pp | +1.0 pp |
| Sep 2024 | +6.6 pp | +6.0 pp | +6.0 pp | 0.0 pp | −1.0 pp |
| Dec 2024 | +2.5 pp | +6.0 pp | +9.0 pp | +5.0 pp | −4.0 pp |
| Mar 2025 | +10.5 pp | +2.0 pp | +9.0 pp | +7.0 pp | +3.0 pp |
| Jun 2025 | −1.0 pp | +1.0 pp | +8.0 pp | +10.0 pp | −8.0 pp |
| Sep 2025 | +3.0 pp | +2.0 pp | +11.0 pp | +9.0 pp | −7.0 pp |
| Dec 2025 | +5.0 pp | +2.0 pp | +13.0 pp | +7.0 pp | −5.0 pp |
| Mar 2026 | +4.0 pp | −1.0 pp | +14.0 pp | +4.0 pp | −8.0 pp |
| Jun 2026 | +1.0 pp | +11.0 pp | +9.0 pp | +8.0 pp | +2.0 pp |
| Sep 2026 | +6.0 pp | +10.0 pp | +9.0 pp | +10.0 pp | −2.0 pp |
24 of 24 companies report OPM, 24 of 24 margin change.
OPM · highest
- 1Anthem Biosciences LtdANTHEM46%
- 2Divis Laboratories LtdDIVISLAB43%
- 3Acutaas Chemicals LtdACUTAAS40%
- 4Laurus Labs LtdLAURUSLABS34%
- 5Concord Biotech LtdCONCORDBIO34%
Margin change · fastest expanders
- 1Divis Laboratories LtdDIVISLAB+10.0 pp
- 2Laurus Labs LtdLAURUSLABS+10.0 pp
- 3Acutaas Chemicals LtdACUTAAS+9.0 pp
- 4Morepen Laboratories LtdMOREPENLAB+9.0 pp
- 5Hikal LtdHIKAL+8.1 pp
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Anthem Biosciences Ltd ANTHEM | 46% | +6.0 pp | Sep 2026 |
| Divis Laboratories Ltd DIVISLAB | 43% | +10.0 pp | Sep 2026 |
| Acutaas Chemicals Ltd ACUTAAS | 40% | +9.0 pp | Sep 2026 |
| Laurus Labs Ltd LAURUSLABS | 34% | +10.0 pp | Sep 2026 |
| Concord Biotech Ltd CONCORDBIO | 34% | −2.0 pp | Sep 2026 |
| OneSource Specialty Pharma Ltd ONESOURCE | 32% | +4.0 pp | Sep 2026 |
| Blue Jet Healthcare Ltd BLUEJET | 32% | −1.0 pp | Sep 2026 |
| Sai Life Sciences Ltd SAILIFE | 28% | +1.0 pp | Sep 2026 |
| Shilpa Medicare Ltd SHILPAMED | 27% | −2.0 pp | Sep 2026 |
| Gland Pharma Ltd GLAND | 26% | +5.0 pp | Sep 2026 |
| Neuland Laboratories Ltd NEULANDLAB | 22% | −8.0 pp | Sep 2026 |
| Granules India Ltd GRANULES | 22% | +1.0 pp | Sep 2026 |
| Supriya Lifescience Ltd SUPRIYA | 22% | −14.0 pp | Sep 2026 |
| SMS Pharmaceuticals Ltd SMSPHARMA | 21% | +1.0 pp | Sep 2026 |
| Syngene International Ltd SYNGENE | 18% | −4.0 pp | Sep 2026 |
| Solara Active Pharma Sciences Ltd SOLARA | 18% | +7.0 pp | Sep 2026 |
| Morepen Laboratories Ltd MOREPENLAB | 16% | +9.0 pp | Sep 2026 |
| IOL Chemicals & Pharmaceuticals Ltd IOLCP | 14% | +4.0 pp | Sep 2026 |
| Piramal Pharma Ltd PPLPHARMA | 13% | +5.6 pp | Sep 2026 |
| Windlas Biotech Ltd WINDLAS | 11% | −2.0 pp | Sep 2026 |
| Hikal Ltd HIKAL | 10% | +8.1 pp | Sep 2026 |
| Jubilant Pharmova Ltd JUBLPHARMA | 10% | −7.0 pp | Sep 2026 |
| Dishman Carbogen Amcis Ltd DCAL | 9.0% | −14.0 pp | Sep 2026 |
| Cohance Lifesciences Ltd COHANCE | 7.4% | −14.4 pp | Sep 2026 |
What to watch
Watch whether the next two comparable periods confirm the current margin change rather than reversing it.
Which API and CDMO Pharma companies earn the most profit?
Divis Laboratories Ltd has the highest Net profit among the 24 Pharma - API & CRAMS companies compared here, at ₹3,363 crore. Laurus Labs Ltd is next at ₹1,332 crore. Shilpa Medicare Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Divis Laboratories Ltd earns the most, ₹3,363 crore of profit over the last 12 months, 152.5% above Laurus Labs Ltd. Shilpa Medicare Ltd shows at least 100% on the scoring scale (141.3% in full) growth from a profit base of ₹333 crore. A fast rate from a small base matters less than a large profit that keeps coming.
What this means: Divis Laboratories Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profit · company comparison
Net profit · largest
- 1Divis Laboratories LtdDIVISLAB₹3,360 cr
- 2Laurus Labs LtdLAURUSLABS₹1,330 cr
- 3Gland Pharma LtdGLAND₹1,240 cr
- 4Granules India LtdGRANULES₹714 cr
- 5Anthem Biosciences LtdANTHEM₹614 cr
Profit growth · fastest growers
- 1Shilpa Medicare LtdSHILPAMED100%
- 2Acutaas Chemicals LtdACUTAAS96%
- 3Laurus Labs LtdLAURUSLABS95%
- 4Morepen Laboratories LtdMOREPENLAB91%
- 5Neuland Laboratories LtdNEULANDLAB88%
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Divis Laboratories Ltd DIVISLAB | ₹1,130 cr | 64% | Sep 2026 |
| Laurus Labs Ltd LAURUSLABS | ₹436 cr | 125% | Sep 2026 |
| Gland Pharma Ltd GLAND | ₹291 cr | 58% | Sep 2026 |
| Anthem Biosciences Ltd ANTHEM | ₹211 cr | 22% | Sep 2026 |
| Granules India Ltd GRANULES | ₹182 cr | 39% | Sep 2026 |
| Acutaas Chemicals Ltd ACUTAAS | ₹123 cr | 71% | Sep 2026 |
| Blue Jet Healthcare Ltd BLUEJET | ₹103 cr | 98% | Sep 2026 |
| Sai Life Sciences Ltd SAILIFE | ₹98 cr | 17% | Sep 2026 |
| Morepen Laboratories Ltd MOREPENLAB | ₹89 cr | 117% | Sep 2026 |
| Shilpa Medicare Ltd SHILPAMED | ₹79 cr | 80% | Sep 2026 |
| Concord Biotech Ltd CONCORDBIO | ₹70 cr | 11% | Sep 2026 |
| IOL Chemicals & Pharmaceuticals Ltd IOLCP | ₹65 cr | 117% | Sep 2026 |
| OneSource Specialty Pharma Ltd ONESOURCE | ₹57 cr | 470% | Sep 2026 |
| Neuland Laboratories Ltd NEULANDLAB | ₹52 cr | −46% | Sep 2026 |
| SMS Pharmaceuticals Ltd SMSPHARMA | ₹40 cr | 60% | Sep 2026 |
| Syngene International Ltd SYNGENE | ₹32 cr | −52% | Sep 2026 |
| Jubilant Pharmova Ltd JUBLPHARMA | ₹31 cr | −74% | Sep 2026 |
| Supriya Lifescience Ltd SUPRIYA | ₹29 cr | −42% | Sep 2026 |
| Solara Active Pharma Sciences Ltd SOLARA | ₹28 cr | 45% | Sep 2026 |
| Windlas Biotech Ltd WINDLAS | ₹18 cr | 0.0% | Sep 2026 |
| Piramal Pharma Ltd PPLPHARMA | ₹5 cr | −106% | Sep 2026 |
| Cohance Lifesciences Ltd COHANCE | ₹2.3 cr | −97% | Sep 2026 |
| Hikal Ltd HIKAL | −₹6.1 cr | −71% | Sep 2026 |
| Dishman Carbogen Amcis Ltd DCAL | −₹67 cr | −203% | Sep 2026 |
What to watch
Watch whether the next two comparable periods confirm the current profit growth rather than reversing it.
Which API and CDMO Pharma companies earn the best return on capital?
Acutaas Chemicals Ltd has the highest ROCE among the 24 Pharma - API & CRAMS companies compared here, at 31.6%. Anthem Biosciences Ltd is next at 30.4%. The same company also has the highest ROCE change, at +12 percentage points. 24 of 24 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: Acutaas Chemicals Ltd leads ROCE at 31.6%, 1.2 percentage points above Anthem Biosciences Ltd. A high return reported once may be one good year; a high return reported year after year shows a lasting business.
What this means: Acutaas Chemicals Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
Return on capital · company comparison
Withheld from this chart: Acutaas Chemicals Ltd (ACUTAAS): its two data sources disagree by up to 22% on reported income across 15 comparable periods, so its derived ratios are withheld; Cohance Lifesciences Ltd (COHANCE): its two data sources disagree by up to 548% on reported income across 16 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn, the gap is a decision, not missing data.
ROCE · highest
- 1Anthem Biosciences LtdANTHEM30%
- 2Neuland Laboratories LtdNEULANDLAB27%
- 3Blue Jet Healthcare LtdBLUEJET26%
- 4Supriya Lifescience LtdSUPRIYA25%
ROCE change · fastest improvers
- 1Neuland Laboratories LtdNEULANDLAB+11.4 pp
- 2Laurus Labs LtdLAURUSLABS+8.4 pp
- 3Morepen Laboratories LtdMOREPENLAB+8.1 pp
- 4IOL Chemicals & Pharmaceuticals LtdIOLCP+5.5 pp
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Neuland Laboratories Ltd NEULANDLAB | 25% | +11.4 pp | Sep 2026 |
| Laurus Labs Ltd LAURUSLABS | 25% | +8.4 pp | Sep 2026 |
| Divis Laboratories Ltd DIVISLAB | 22% | +4.3 pp | Sep 2026 |
| Anthem Biosciences Ltd ANTHEM | 22% | −1.9 pp | Sep 2026 |
| Supriya Lifescience Ltd SUPRIYA | 18% | −2.7 pp | Sep 2026 |
| Sai Life Sciences Ltd SAILIFE | 17% | +1.5 pp | Sep 2026 |
| Concord Biotech Ltd CONCORDBIO | 16% | −4.6 pp | Sep 2026 |
| Morepen Laboratories Ltd MOREPENLAB | 15% | +8.1 pp | Sep 2026 |
| SMS Pharmaceuticals Ltd SMSPHARMA | 15% | +0.9 pp | Sep 2026 |
| Blue Jet Healthcare Ltd BLUEJET | 15% | −18.0 pp | Sep 2026 |
| Granules India Ltd GRANULES | 14% | −2.3 pp | Sep 2026 |
| IOL Chemicals & Pharmaceuticals Ltd IOLCP | 14% | +5.5 pp | Sep 2026 |
| Gland Pharma Ltd GLAND | 14% | +4.1 pp | Sep 2026 |
| Windlas Biotech Ltd WINDLAS | 14% | −0.2 pp | Sep 2026 |
| Shilpa Medicare Ltd SHILPAMED | 11% | +2.0 pp | Sep 2026 |
| Syngene International Ltd SYNGENE | 8.4% | −3.1 pp | Sep 2026 |
| Solara Active Pharma Sciences Ltd SOLARA | 7.7% | +0.7 pp | Sep 2026 |
| Jubilant Pharmova Ltd JUBLPHARMA | 6.5% | −1.9 pp | Sep 2026 |
| Hikal Ltd HIKAL | 6.4% | +1.6 pp | Sep 2026 |
| Piramal Pharma Ltd PPLPHARMA | 2.4% | −0.3 pp | Sep 2026 |
| Dishman Carbogen Amcis Ltd DCAL | 2.1% | −2.0 pp | Sep 2026 |
| OneSource Specialty Pharma Ltd ONESOURCE | 1.1% | −0.9 pp | Sep 2026 |
What to watch
Watch whether the next two comparable periods confirm the current roce change rather than reversing it.
How are API and CDMO Pharma stocks valued against growth and quality?
Granules India Ltd has the lowest PEG among the 24 Pharma - API & CRAMS companies compared here, at 1.35×. Shilpa Medicare Ltd is next at 1.42×. Morepen Laboratories Ltd has the lowest P/E at 26.9×, so level and change sit with different companies. 12 of 24 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: Granules India Ltd has the lowest comparable PEG at 1.35×, 4.9% below Shilpa Medicare Ltd. That would need today's multiple, the company's own history and steady growth to agree.
What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
Valuation · company comparison
PEG, by reported quarter
- Granules India 0.9
- Concord Biotech 3.4
- Blue Jet Healthcare 1.4
- Gland Pharma 0.9
| Quarter | Granules India | Concord Biotech | Blue Jet Healthcare | Gland Pharma |
|---|---|---|---|---|
| Dec 2021 | — | — | — | — |
| Mar 2022 | — | — | — | — |
| Jun 2022 | — | — | — | 1.7 |
| Sep 2022 | — | — | — | 3.6 |
| Dec 2022 | — | — | — | — |
| Mar 2023 | 0.7 | — | — | — |
| Jun 2023 | 0.5 | — | — | — |
| Sep 2023 | 3.5 | — | — | — |
| Dec 2023 | — | — | — | — |
| Mar 2024 | — | — | — | — |
| Jun 2024 | — | — | — | — |
| Sep 2024 | 2.0 | — | — | — |
| Dec 2024 | 1.2 | 1.8 | 5.7 | — |
| Mar 2025 | — | 7.6 | 1.4 | — |
| Jun 2025 | 1.4 | 2.1 | — | — |
| Sep 2025 | — | — | — | 6.3 |
| Dec 2025 | — | 4.8 | — | 2.4 |
| Mar 2026 | — | 3.4 | — | 1.5 |
| Jun 2026 | 1.4 | — | — | — |
| Sep 2026 | 0.9 | — | — | 0.9 |
P/E, by reported quarter
- Granules India 32.2×
- Shilpa Medicare 70.8×
- Concord Biotech 53.6×
- Blue Jet Healthcare 42.0×
- Gland Pharma 41.7×
| Quarter | Granules India | Shilpa Medicare | Concord Biotech | Blue Jet Healthcare | Gland Pharma |
|---|---|---|---|---|---|
| Dec 2021 | 17.5× | 147.8× | — | — | 56.8× |
| Mar 2022 | 18.4× | 104.2× | — | — | 44.3× |
| Jun 2022 | 15.4× | 63.6× | — | — | 35.9× |
| Sep 2022 | 20.4× | 61.8× | — | — | 31.6× |
| Dec 2022 | 15.9× | 113.0× | — | — | 25.2× |
| Mar 2023 | 13.8× | 382.0× | — | — | 21.1× |
| Jun 2023 | 13.9× | 396.9× | — | — | 21.3× |
| Sep 2023 | 19.7× | −260.9× | 47.8× | — | 35.3× |
| Dec 2023 | 24.9× | −3,941.6× | 64.8× | 40.0× | 43.2× |
| Mar 2024 | 26.4× | 125.6× | 52.2× | 41.6× | 43.8× |
| Jun 2024 | 29.5× | 180.6× | 54.5× | 41.0× | 38.9× |
| Sep 2024 | 27.4× | 192.1× | 68.4× | 54.4× | 40.7× |
| Dec 2024 | 29.2× | 130.9× | 69.1× | 54.8× | 43.1× |
| Mar 2025 | 24.6× | 76.7× | 53.9× | 65.4× | 37.2× |
| Jun 2025 | 25.2× | 93.3× | 51.3× | 49.2× | 42.0× |
| Sep 2025 | 26.2× | 57.6× | 46.1× | 31.2× | 41.9× |
| Dec 2025 | 29.3× | 40.0× | 39.5× | 26.1× | 34.5× |
| Mar 2026 | 28.5× | 38.1× | 29.9× | 20.3× | 32.9× |
| Jun 2026 | 31.4× | 47.9× | 37.9× | 36.9× | 36.6× |
| Sep 2026 | 32.2× | 70.8× | 53.6× | 42.0× | 41.7× |
12 of 24 companies report PEG, 21 of 24 P/E.
PEG · lowest PEG
- 1Granules India LtdGRANULES1.4
- 2Shilpa Medicare LtdSHILPAMED1.4
- 3Concord Biotech LtdCONCORDBIO1.5
- 4Blue Jet Healthcare LtdBLUEJET1.8
- 5Gland Pharma LtdGLAND1.8
P/E · lowest P/E
- 1Morepen Laboratories LtdMOREPENLAB26.9×
- 2IOL Chemicals & Pharmaceuticals LtdIOLCP27.4×
- 3Supriya Lifescience LtdSUPRIYA27.9×
- 4Granules India LtdGRANULES28.2×
- 5Windlas Biotech LtdWINDLAS30.9×
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| Syngene International Ltd SYNGENE | 7.9 | 51.6× | Sep 2026 |
| Supriya Lifescience Ltd SUPRIYA | 3.4 | 39.8× | Sep 2026 |
| Hikal Ltd HIKAL | 3.4 | 63.3× | Sep 2026 |
| Concord Biotech Ltd CONCORDBIO | 3.4 | 53.6× | Sep 2026 |
| Windlas Biotech Ltd WINDLAS | 3.0 | 35.1× | Sep 2026 |
| Laurus Labs Ltd LAURUSLABS | 3.0 | 99.0× | Sep 2026 |
| Divis Laboratories Ltd DIVISLAB | 2.9 | 85.2× | Sep 2026 |
| Anthem Biosciences Ltd ANTHEM | 2.7 | 82.4× | Sep 2026 |
| Morepen Laboratories Ltd MOREPENLAB | 2.1 | 57.1× | Sep 2026 |
| SMS Pharmaceuticals Ltd SMSPHARMA | 1.6 | 42.8× | Sep 2026 |
| Blue Jet Healthcare Ltd BLUEJET | 1.4 | 42.0× | Sep 2026 |
| Neuland Laboratories Ltd NEULANDLAB | 1.1 | 55.6× | Sep 2026 |
| Granules India Ltd GRANULES | 0.9 | 32.2× | Sep 2026 |
| Gland Pharma Ltd GLAND | 0.9 | 41.7× | Sep 2026 |
| IOL Chemicals & Pharmaceuticals Ltd IOLCP | 0.7 | 32.9× | Sep 2026 |
| Sai Life Sciences Ltd SAILIFE | — | 90.8× | Sep 2026 |
| Acutaas Chemicals Ltd ACUTAAS | — | 69.4× | Sep 2026 |
| Piramal Pharma Ltd PPLPHARMA | — | −131.5× | Sep 2026 |
| Shilpa Medicare Ltd SHILPAMED | — | 70.8× | Sep 2026 |
| OneSource Specialty Pharma Ltd ONESOURCE | — | −10,764.2× | Sep 2026 |
| Cohance Lifesciences Ltd COHANCE | — | 163.2× | Sep 2026 |
| Jubilant Pharmova Ltd JUBLPHARMA | — | 43.3× | Sep 2026 |
| Solara Active Pharma Sciences Ltd SOLARA | — | 840.1× | Sep 2026 |
| Dishman Carbogen Amcis Ltd DCAL | — | 145.4× | Sep 2026 |
What to watch
Watch whether the next two comparable periods confirm the current p/e rather than reversing it.
Which stock lists do API and CDMO Pharma companies appear on?
Pharma - API & CRAMS companies show up on 7 of our India lists. The most are on the pharma stocks list (24 companies).
What can make this comparison misleading?
This Pharma - API & CRAMS comparison names 5 specific ways its own evidence can mislead, all listed below. All 24 companies here report on comparable dates, so no rank carries a stale marker. 2 have second-source figures left out because the two sources disagree. A high growth rate can still come from a very small starting figure.
Keep these limits visible
- A high growth rate can come from a very small starting figure. The page keeps level and change separate for that reason.
- A high ROCE can be temporary, or look high because the capital base is small. It is best read beside margin, cash flow and how much is spent back on the business.
- The 4-Factor Sector Score ranks published data only. Management quality, upcoming events and risks are not part of it.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 2 companies are missing from the second-source figures on purpose: the two sources disagree, so nothing from the second is drawn. Those rows have less evidence; that does not make the business weaker.
How was this comparison built?
This comparison is built from the reported filings of 24 Pharma - API & CRAMS companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Sep 2026 and market data through 13 November 2026.
2 of 24 companies have a second data feed that is known to disagree with the primary source, so nothing from it is drawn: Acutaas Chemicals Ltd (ACUTAAS): its two data sources disagree by up to 22% on reported income across 15 comparable periods, so its derived ratios are withheld; Cohance Lifesciences Ltd (COHANCE): its two data sources disagree by up to 548% on reported income across 16 comparable periods, so its derived ratios are withheld.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree, the figures are simply used. Where there is too little shared history to compare, the figures are still drawn, they are the only evidence there is, and marked unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
What else do people ask about API and CDMO Pharma stocks?
These 24 answers restate the Pharma - API & CRAMS comparison above in question form. Every one is computed from the same 24 companies and the same reported filings as the rankings and charts, current through Sep 2026. Price and relative-strength answers run through 13 November 2026. Nothing here is estimated, and none of it is a recommendation.
Is the API and CDMO Pharma sector outperforming NIFTY 500?
Pharma - API & CRAMS has done better than the NIFTY 500 by 34.7% over 52 weeks and by 11.8% over 13 weeks.
13 of 24 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months), and 8 of the 18 with a long enough price history are ahead of the industry itself.
Which API and CDMO Pharma company is largest by revenue?
Divis Laboratories Ltd leads with revenue of ₹12,191 crore, based on 24 of 24 comparable companies through Sep 2026.
Which API and CDMO Pharma company is growing fastest?
Neuland Laboratories Ltd has the fastest current revenue growth at 50.5%, across 24 of 24 comparable companies.
Which API and CDMO Pharma company has the strongest 4-Factor Sector Score?
Laurus Labs Ltd ranks first at 74.4 out of 100, with 93% of the evidence available. The score ranks published data; it is not a recommendation.
Which API and CDMO Pharma company has the lowest comparable PEG?
Granules India Ltd has the lowest comparable PEG at 1.35, among 12 of 24 companies whose earnings and growth are steady enough for the ratio to mean anything.
How much history does this API and CDMO Pharma comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Sep 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four parts add up directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or old evidence moves only that part toward the middle.
Is there a Nifty API and CDMO Pharma index?
The exchange runs Nifty indices for several broad sectors, such as Nifty Bank, Nifty IT and Nifty Pharma, but not for every smaller group on this site.
Whether or not an official Nifty index covers Pharma - API & CRAMS, this page builds its own equal-weight basket of 24 listed Pharma - API & CRAMS companies: one company, one vote, whatever its size, so no single large company dominates. Figures are as of Sep 2026.
Which are the best API and CDMO Pharma stocks in India?
Ranked by this page's four-factor score, Laurus Labs Ltd comes first among 24 listed Pharma - API & CRAMS companies, followed by Acutaas Chemicals Ltd. That is a ranking of published data (earnings, quality, valuation and share-price behaviour as of Sep 2026), not a recommendation.
How many API and CDMO Pharma stocks are listed in India?
This comparison covers 24 listed Pharma - API & CRAMS companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Sep 2026.
Which API and CDMO Pharma company is the biggest?
Divis Laboratories Ltd is the largest, with revenue of ₹12,191 crore over the last 12 months, ahead of Piramal Pharma Ltd at ₹9,779 crore. That covers 24 of 24 companies with comparable reporting through Sep 2026.
Which API and CDMO Pharma company has the best profit margins?
Anthem Biosciences Ltd has the highest operating margin at 45.6%, from 24 of 24 comparable companies. Divis Laboratories Ltd shows the biggest recent improvement, at +10 percentage points. A high margin matters most when it is steady or rising, not when it is at a peak.
Which API and CDMO Pharma company makes the most profit?
Divis Laboratories Ltd earns the most, at ₹3,363 crore of net profit over the last 12 months, from 24 of 24 comparable companies.
Shilpa Medicare Ltd has the fastest profit growth at the 100% cap of the scoring scale, though growth off a small or recovering profit base overstates how much has actually changed.
Which API and CDMO Pharma company earns the highest return on capital?
Acutaas Chemicals Ltd leads on return on capital employed at 31.6%, across 24 of 24 companies. A high return that repeats for years shows a lasting business, while a single high reading can come from a small capital base or one good year.
Which API and CDMO Pharma stock has the lowest PEG ratio?
On PEG (where a lower number means a lower price for what the company earns), Granules India Ltd has the lowest at 1.35×. Only 12 of 24 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a ranking of the whole industry.
A low multiple is a reason to look closer at the business, not a conclusion on its own.
Is the API and CDMO Pharma sector beating the market?
Pharma - API & CRAMS has done better than the NIFTY 500 by 34.7% over the last 52 weeks and by 11.8% over 13 weeks, measured on an equal-weight index of its current members.
Inside the sector, 13 of the 24 companies we track are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which API and CDMO Pharma stock has the strongest price momentum?
Shilpa Medicare Ltd has the strongest relative strength against the NIFTY 500, meaning its share price has done best against the index. A price can move well before the business results back it up, and sometimes without them.
Which API and CDMO Pharma company has the highest 4-Factor score?
Laurus Labs Ltd scores 74.4 out of 100, with 93% of the evidence available, from 32.2 points on growth and earnings, 17.4 on capital efficiency, 7.1 on valuation and 17.7 on relative strength. It ranks published data only; management quality, upcoming events and risks are not part of the score.
How many API and CDMO Pharma companies does this comparison cover, and over what period?
This comparison covers 24 listed companies over up to 20 reported quarters of fundamentals, ending Sep 2026, plus weekly price and relative-strength history. Membership is the full sector list, nothing is dropped for having thin data.
What is the total market cap of the API and CDMO Pharma sector?
The 24 Pharma - API & CRAMS companies on this page carry ₹8,12,768 crore of combined market value. Divis Laboratories Ltd is the largest at ₹2,93,316 crore, about 36% of the sector's total on its own. Market value moves with price, so this reading is dated 13 November 2026.
What is the API and CDMO Pharma sector's P/E ratio?
The median price-to-earnings ratio across the 24 Pharma - API & CRAMS companies on this page is 56.5×, measured on the 21 that report a comparable figure.
A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 13 November 2026.
How is the API and CDMO Pharma sector performing?
13 of the 24 Pharma - API & CRAMS companies we track are doing better than the NIFTY 500 on relative strength (how a share price has done against the index over recent months).
The sector itself is 34.7% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing figures are never estimated, copied forward or swapped for a similar-looking line, and a company with missing evidence has its score pulled toward the middle rather than scored as bad.
Is this advice?
No, every figure here is worked out by code from company filings and market data, for research. It does not account for your situation and is not a substitute for advice from a registered adviser.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
Every India sector against its index · What changed this week · Plain-text data
Sector Alpha, written by code from the published numbers · Fundamentals through Sep 2026 · Prices through 13 November 2026. Every ranking is worked out by code from reported figures. Missing values stay missing.
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.